All In Biotech

Drug Trial Radar · NCT02859857

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas

Last checked: Nov 20, 2026Latest source record: Jul 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Sep 1, 2016

Primary completion

Jun 17, 2019

Study completion Jun 15, 2020

Sponsor

Lead sponsor
Bexion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
CTI Clinical Trial and Consulting Services
First posted
Aug 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to characterize the safety profile and determine the maximum tolerate dose (MTD) of BXQ-350, when given as a single agent at escalating doses, according to the investigational product (IP) related dose-limiting toxicities (DLTs) in patients with advanced solid tumors. Secondarily to assess the preliminary antitumor activity of BXQ-350 in solid tumors and recurrent high grade gliomas.

Conditions

  • Neoplasms

Interventions

  • BXQ-350Drug

    BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1-MTDTime frame: 12 months
  2. Part 2-RECISTTime frame: 12 months
  3. Part 2-RANOTime frame: 12 months
  4. Part 3 - RECISTTime frame: 12 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico

  • University of Cincinnati Barrett Center

    Cincinnati, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.